Please wait a minute...
Reviews in Cardiovascular Medicine  2018, Vol. 19 Issue (3): 97-101     DOI: 10.31083/j.rcm.2018.03.3181
Original Research Previous articles | Next articles
Activation of β1-adrenoceptors may not be involved in arrhythmogenesis in ischemic heart disease
Adriana D. Adameova1, Sukhwinder K. Bhullar2, Vijayan Elimban2, Naranjan S. Dhalla2, *()
1 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic, 832 32
2 2Department of Physiology & Pathophysiology and Institute of Cardiovascular Sciences, Max Rady College of Medicine, St.Boniface Hospital Albrechtsen Research Centre, University of Manitoba, Winnipeg, R2H 2A6, Canada
Download:  PDF(503KB)  ( 1518 )
Export:  BibTeX | EndNote (RIS)      
Although ischemic heart disease is invariably associated with marked activation of sympathetic nervous system, elevated levels of circulating catecholamines and lethal ventricular arrhythmias, the mechanisms of arrhythmogenesis due to myocardial ischemia are not fully understood. Since catecholamines are known to produce stimulatory effects in the heart mainly by acting on β1-adrenoceptors, this study was undertaken to test the involvement of these receptors in the development of arrhythmias due to myocardial infarction (MI) induced upon occluding the left coronary artery in rats for a period of 2 h. The animals were treated with or without atenolol (20 mg/kg; daily), a selective β1-adrenoceptors blocker, for 14 days before inducing MI. No alterations in the number of MIinduced episodes and incidence or duration of different types of arrhythmias were observed. In fact, the incidence of trigemines and reversible ventricular fibrillation due to MI were significantly increased in the atenolol-treated animals. These observations support the view that the activation of β;1-adrenoceptors may not be exclusively involved in the development of arrhythmias during the occurrence of ischemic heart disease and other mechanisms can underlie the electric instability of such damaged heart.
Key words:  Arrhythmias      β1-adrenoceptors      atenolol      myocardial ischemia     
Published:  30 September 2018     
*Corresponding Author(s):  Naranjan S. Dhalla, E-mail:   

Cite this article: 

Adriana D. Adameova, Sukhwinder K. Bhullar, Vijayan Elimban, Naranjan S. Dhalla. Activation of β1-adrenoceptors may not be involved in arrhythmogenesis in ischemic heart disease. Reviews in Cardiovascular Medicine, 2018, 19(3): 97-101.

URL:     OR

[1] Abendroth RR, Meesmann W, Stephan K, et al. Effects of the betablocking agent atenolol on arrhythmias, especially ventricular fibrillation and ventricular fibrillation threshold after acute experimental coronary occlusion. Z Kardiol. 1977;66:341-350.
[2] Ablad B, Bjuro T, Bjorkman J-A, et al. Prevention of ventricular fibrillation requires central β-adrenoceptor blockade in rabbits. Scand Cardiovasc J. 2007;41:221-229.
[3] Adameova A, Abdellatif Y, Dhalla NS. Role of the excessive amounts of circulating catecholamines and glucocorticoids in stressinduced heart disease. Can J Physiol Pharmacol. 2009;87:493- 414.
[4] Adameova A, Elimban V, Ganguly PK, et al. Both β1 adrenoceptors and AT1 receptors may not be involved in the catecholamineinduced lethal arrhythmias. Can J Physiol Pharmacol. 2019.
[5] Adameova A, Kuzelova M, Andelova E, et al. Hypercholesterolemia abrogates an increased resistance of diabetic rat hearts to ischemia-reperfusion injury. Mol Cell Biochem. 2007;295:129- 136.
[6] Babick A, Elimban V, Zieroth S et al. Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction. J Cell Physiol. 2013;228:2063-2070.
[7] Barta J, Sanganalmath SK, Kumamoto H, et al. Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality. Cardiovasc Toxicol. 2008;8:127- 135.
[8] Brasil D, Temsah RM, Kumar K, et al. Blockade of 5-HT2A receptors by sarpogrelate protects the heart against myocardial infarction in rat. J Cardiovasc Pharmacol Therapeut. 2002;7:53-59.
[9] Clark C, Foreman MI, Kane KA, et al. Coronary artery ligation in anesthetized rats as a method for the production of experimental dysrhythmias and for the determination of infarct size. J Pharmacol Meth. 1980;3:357-368.
[10] Clements-Jewery H, Andrag E, Hearse DJ, et al. Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats. Br J Pharmac. 2009;156:444- 453.
[11] Curtis MJ, Hancox JC, Farkas A, et al. The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther. 2013;139:213- 248.
[12] Curtis MJ, MacLeod BA, Walker MJ. Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat. Br J Pharmacol. 1984;83:373-385.
[13] Daugherty A, Frayn KN, Redfern WS, et al. The role of catecholamines in the production of ischaemia-induced ventricular arrhythmias in the rat in vivo and in vitro. Br J Pharmac. 1986;87:265-277.
[14] de Boer RA, van Geel PP, Pinto YM, et al. Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression. J Cardiovasc Pharmacol. 2002;39:610-619.
[15] Dhalla NS, Adameova A, Kaur M. Role of catecholamine oxidation in sudden cardiac death. Fund Clin Pharmacol. 2010;24:539-546.
[16] Dhalla NS, Afzal N, Beamish RE, et al. Pathophysiology of cardiac dysfunction in congestive heart failure. Can J Cardiol. 1993;9:873-887.
[17] Dhalla NS. Formation of aminochrome leads to cardiac dysfunction and sudden cardiac death. Circ Res. 2018;123:409-411.
[18] Dhalla NS, Elmoselhi AB, Hata T et al. Status of myocardial antioxidants in ischemiareperfusion injury. Cardiovasc Res. 2000a;47:446-456.
[19] Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertension. 2000b;18:655-673.
[20] Dixon IM, Lee SL, Dhalla NS. Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ Res. 1990;66:782-788.
[21] Fearon RE. Propranolol in the prevention of ventricular fibrillation due to experimental coronary artery occlusion. Am J Cardiol. 1967;20:222-228.
[22] Fitzgerald JD. The effects of β-adrenoceptor blocking drugs on early arrhythmias in experimental and clinical myocardial ischemia. In: J. R. Parratt, editors. Early Arrhythmias Resulting from Myocardial Ischemia. London: Macmillan. 1982;295-316.
[23] Fleetwood G, Boutinet S, Meier M, et al. Involvement of the reninangiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J Cardiovasc Pharmacol. 1991;17:351-356.
[24] Freemantle N, Cleland J, Young P, et al. β-Blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J. 1999;318:1730-1737.
[25] Lepran I, Koltai M, Siegmund W, et al. Coronary artery ligation, early arrhythmias, and determination of the ischemic area in conscious rats. J Pharmacol Meth. 1983;9:219-230.
[26] Matsuo K, Kumagai K, Annoura M, et al. Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs. Pacing Clin Electrophysiol. 1997;20:938-945.
[27] Opitz CF, Mitchell GF, Pfeffer MA, et al. Arrhythmias and death after coronary artery occlusion in the rat. Continuous telemetric ECG monitoring in conscious, untethered rats. Circulation. 1995;92:253-261.
[28] Randhawa AS, Dhadial RS, Adameova A, et al. The role of the sympathetic nervous system in sudden cardiac death. Curr Res Cardiol. 2016;3:83-88.
[29] Rosati RA, Alexndra JA, Wallace AG, et al. Failure of beta-adrenergic blockade to alter ventricular fibrillation threshold in the dog. Evidence for extra-adrenergic effects of pronethalol. Circ Res. 1966;19:721-725.
[30] Shao Q, Takeda N, Temsah R, et al. Prevention of hemodynamic changes due to myocardial infarction by early treatment of rats with imidapril. Cardiovasc Pathol. 1996;1:180-186.
[31] Taylor B, Moffett BS, Krenek M, et al. Race contributes to beta-blocker efficacy in pediatric patients with arrhythmias. Pediatr Cardiol. 2014;35:641-644.
[32] Walker MJ, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc Res. 1988;22:447-455.
[1] Umair Khalid, Ali Massumi, Aziz Shaibani. Swallowing-induced Supraventricular Tachyarrhythmia[J]. Reviews in Cardiovascular Medicine, 2017, 18(1): 53-58.
[2] Emily Tat, Richard Cheng, Jeffrey S. Helfenstein. Forty Years of Chest Pain: A Case Report and Contemporary Review of the Diagnostic and Therapeutic Options for Myocardial Bridging[J]. Reviews in Cardiovascular Medicine, 2016, 17(1-2): 69-75.
[3] Bernard Abi-Saleh, Christopher Malozzi, Edriss Charaf, Bassam Omar, Clara Massey, Maurice Khoury, Sumit Verma. Worsening Thoracic Impedance as a Ventricular Tachyarrhythmia Risk[J]. Reviews in Cardiovascular Medicine, 2014, 15(3): 226-231.
[4] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49-55.
[5] Eugenio Cingolani, Norman E. Lepor, Bramah N. Singh. The Electrophysiological Properties of Ranolazine: A Metabolic Anti-Ischemic Drug or an Energy-Efficient Antiarrhythmic Agent?[J]. Reviews in Cardiovascular Medicine, 2011, 12(3): 136-142.
[6] Premranjan P. Singh, Richard W. Nesto, David P. Faxon, Norman E. Lepor, Karol E. Watson, Alice K. Jacobs, Peter A. McCullough. Best of the AHA Scientific Sessions 2006[J]. Reviews in Cardiovascular Medicine, 2007, 8(1): 25-35.
[7] Peter A. McCullough. Chronic Angina: New Medical Options for Treatment[J]. Reviews in Cardiovascular Medicine, 2005, 6(3): 152-161.
[8] William F. Fearon, Alan C. Yeung. Evaluating Intermediate Coronary Lesions in the Cardiac Catheterization Laboratory[J]. Reviews in Cardiovascular Medicine, 2003, 4(1): 1-7.
[9] . Best of the ACC Scientific Session 2002[J]. Reviews in Cardiovascular Medicine, 2002, 3(2): 85-104.
[10] . Best of the ACC Scientific Session 2001[J]. Reviews in Cardiovascular Medicine, 2001, 2(3): 143-159.
[11] Vatsal H. Mody, David P. Faxon. Management of Unstable Angina: Integrating the New Approaches[J]. Reviews in Cardiovascular Medicine, 2000, 1(2): 104-119.
No Suggested Reading articles found!